The private equity healthcare investment playbook is undergoing its most profound structural realignment in more than two decades. The historical model, predicated on low cost leverage, fragmented clinical practice roll-ups, valuation multiple arbitrage and aggressive billing optimisation, has collided with systemic economic, legal and operational headwinds. Across the transaction landscape, an aggressive cross-agency federal antitrust apparatus, an expanding patchwork of sta